Melanoma experts contribute to consensus project

An ongoing e-Delphi consensus study led by the Lovat group highlights the challenges melanoma experts face with the limited resources available to meet the requirements set by current UK guidelines. More than 75% of survey respondents felt that AMBLor, a novel prognostic biomarker for identifying genuinely low risk subsets of AJCC stage I/II cutaneous malignant melanoma, could help to overcome these challenges. Aidan Rose and Penny Lovat present their findings at the Melanoma Focus Meeting, awarded Best Poster Prize at the British Association of Plastic Reconstructive and Aesthetic Surgeons Celtic meeting. Read more here: https://t.co/wuxV4NdGP8